Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study-4

<p><b>Copyright information:</b></p><p>Taken from "Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study"</p><p></p><p>International Journal of Clinical Practice 2007;61(10):1671-1676.</p><p>Published online Jan 2007</p><p>PMCID:PMC2040191.</p><p>© 2007 ALZA Corporation Journal compilation 2007 Blackwell Publishing Ltd</p

Comparison of BPI pain intensity ratings: end of previous opioid stabilisation phase vs

<p><b>Copyright information:</b></p><p>Taken from "Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study"</p><p></p><p>International Journal of Clinical Practice 2007;61(10):1671-1676.</p><p>Published online Jan 2007</p><p>PMCID:PMC2040191.</p><p>© 2007 ALZA Corporation Journal compilation 2007 Blackwell Publishing Ltd</p> end of treatment. Scale: 0, no pain; 10, pain as bad as you can imagine (p ≤ 0.001 for all scores; no adjustment for multiple testing

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study-0

<p><b>Copyright information:</b></p><p>Taken from "Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study"</p><p></p><p>International Journal of Clinical Practice 2007;61(10):1671-1676.</p><p>Published online Jan 2007</p><p>PMCID:PMC2040191.</p><p>© 2007 ALZA Corporation Journal compilation 2007 Blackwell Publishing Ltd</p

Comparison of BPI pain interference ratings: end of previous opioid stabilisation phase vs

<p><b>Copyright information:</b></p><p>Taken from "Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study"</p><p></p><p>International Journal of Clinical Practice 2007;61(10):1671-1676.</p><p>Published online Jan 2007</p><p>PMCID:PMC2040191.</p><p>© 2007 ALZA Corporation Journal compilation 2007 Blackwell Publishing Ltd</p> end of treatment. Scale: 0, no interference; 10, complete interference (p < 0.001 for all scores; no adjustment for multiple testing